Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 9Breast Neoplasms 5Sarcoma 4Recurrence 4Neoplasm Metastasis 4Lymphoma 4Solid Tumors 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Glioblastoma 2Endometrial Neoplasms 2Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Advanced Cancers 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × ridaforolimus × Clear all
NCT00818675 2015-01-21

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Merck Sharp & Dohme LLC

Phase 2 Terminated
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡